ATE389651T1 - Als inhibitoren von c-met geeignete pyrrolzusammensetzungen - Google Patents
Als inhibitoren von c-met geeignete pyrrolzusammensetzungenInfo
- Publication number
- ATE389651T1 ATE389651T1 AT04781443T AT04781443T ATE389651T1 AT E389651 T1 ATE389651 T1 AT E389651T1 AT 04781443 T AT04781443 T AT 04781443T AT 04781443 T AT04781443 T AT 04781443T AT E389651 T1 ATE389651 T1 AT E389651T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- met
- compositions suitable
- compounds
- pyrrole compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49553503P | 2003-08-15 | 2003-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389651T1 true ATE389651T1 (de) | 2008-04-15 |
Family
ID=34193321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04781443T ATE389651T1 (de) | 2003-08-15 | 2004-08-16 | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050101650A1 (de) |
| EP (1) | EP1660487B1 (de) |
| AT (1) | ATE389651T1 (de) |
| AU (1) | AU2004264440B2 (de) |
| CA (1) | CA2536470A1 (de) |
| DE (1) | DE602004012578T2 (de) |
| WO (1) | WO2005016920A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317453B1 (de) * | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazole und ihre verwendung als erk-inhibitoren |
| GB0419192D0 (en) | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| EP1817295B1 (de) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Hsp90-aktivität modulierende triazolverbindungen |
| CN101198590B (zh) | 2005-08-24 | 2012-05-09 | 卫材R&D管理有限公司 | 吡啶衍生物及嘧啶衍生物（3） |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| CA2661333C (en) | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008153730A2 (en) * | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| CN102137939A (zh) * | 2008-08-29 | 2011-07-27 | 霍夫曼-拉罗奇有限公司 | 不依赖vegf的肿瘤的诊断和治疗 |
| CN102405047B (zh) * | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
| NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| US11795160B2 (en) | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
| CA3208490A1 (en) | 2021-02-24 | 2022-09-01 | Aleksandrs Zavoronkovs | Analogs for the treatment of disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010111298A (ko) * | 2000-02-05 | 2001-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | Ｅｒｋ의 억제제로서 유용한 피라졸 조성물 |
| CA2369502A1 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
| EP1317453B1 (de) * | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazole und ihre verwendung als erk-inhibitoren |
| CA2445568A1 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| DE60226154T2 (de) * | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
-
2004
- 2004-08-16 CA CA002536470A patent/CA2536470A1/en not_active Abandoned
- 2004-08-16 US US10/919,774 patent/US20050101650A1/en not_active Abandoned
- 2004-08-16 DE DE602004012578T patent/DE602004012578T2/de not_active Expired - Lifetime
- 2004-08-16 AT AT04781443T patent/ATE389651T1/de not_active IP Right Cessation
- 2004-08-16 WO PCT/US2004/026749 patent/WO2005016920A1/en not_active Ceased
- 2004-08-16 AU AU2004264440A patent/AU2004264440B2/en not_active Ceased
- 2004-08-16 EP EP04781443A patent/EP1660487B1/de not_active Expired - Lifetime
-
2006
- 2006-03-22 US US11/387,126 patent/US7314885B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004012578D1 (de) | 2008-04-30 |
| DE602004012578T2 (de) | 2008-12-11 |
| WO2005016920A1 (en) | 2005-02-24 |
| US7314885B2 (en) | 2008-01-01 |
| AU2004264440A1 (en) | 2005-02-24 |
| EP1660487A1 (de) | 2006-05-31 |
| AU2004264440B2 (en) | 2008-10-23 |
| US20050101650A1 (en) | 2005-05-12 |
| EP1660487B1 (de) | 2008-03-19 |
| CA2536470A1 (en) | 2005-02-24 |
| US20060173055A1 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| ATE420883T1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| UA84930C2 (ru) | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
| ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
| TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
| ATE528309T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |